Associate Director, Scientific Publications

Summit Therapeutics•Palo Alto, CA

1d•$174,000 - $204,000

About The Position

Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit’s core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit’s team is inspired to touch and help change lives through Summit’s clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China’s National Medical Products Administration (NMPA). Summit is headquartered in Miami, Florida, and has additional offices in California, New Jersey, the UK, and Ireland. Summit’s team is inspired to touch and help change lives through Summit’s clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China’s National Medical Products Administration (NMPA). Summit is headquartered in Miami, Florida, and has additional offices in California, New Jersey, the UK, and Ireland. Overview of Role: The Associate Director, Scientific Publications provides strategic and operational leadership for global publication activities, ensuring the timely, compliant, and high-quality dissemination of scientific data. This role combines hands-on operational execution, overseeing publication processes, vendor management, and financial oversight.

Requirements

BA/BS required; advanced degree (PhD, PharmD, MD, MS) preferred.
5+ years in scientific publications, medical affairs, or clinical development within pharma/biotech.
Previous experience in oncology, immunotherapy, or R&D environments.
Proven experience in publication management, vendor oversight, and budget management.
Advanced project management, problem-solving, and organizational abilities.
Ability to manage multiple priorities in a fast-paced, matrixed environment with high attention to detail.

Responsibilities

Define and execute global publication operations strategy aligned with medical and scientific objectives.
Oversee end-to-end publication activities including abstracts, manuscripts, posters, congress deliverables, and digital content.
Contribute to publication planning across disease areas in partnership with Medical Affairs, HEOR, Clinical, and Commercial teams.
Serve as a key liaison across Finance, Regulatory, Legal, and external partners.
Drive continuous improvement through data insights, automation, and AI-enabled tools.
Ensure all publications comply with internal SOPs, ICMJE, and Good Publication Practice (GPP) guidelines.
Manage execution timelines, quality, and submission processes using publication systems (e.g., Datavision).
Support and/or contribute to development of scientific content (abstracts, posters, manuscripts, encore publications).
Facilitate publication approvals and ensure proper archiving and audit readiness.
Develop and track KPIs, dashboards, and reports for publication performance and financial metrics.
Provide data-driven insights to inform decision-making and improve efficiency.
Lead operational support for scientific congresses, including calendar management, poster printing/shipping, and QR code generation.
Coordinate execution of abstracts, posters, and presentations in alignment with publication plans.
Oversee end-to-end vendor lifecycle including selection, contracting, training, performance management, and relationship oversight.
Manage budgets, forecasting, invoice reconciliation, and financial tracking for publication activities.
Deliver training and onboarding for internal teams and vendors on systems and processes.
All other duties as assigned